Evogene Ltd [NASDAQ: EVGN] slipped around -0.12 points on Thursday, while shares priced at $2.28 at the close of the session, down -5.00%.
Compared to the average trading volume of 30.71K shares, EVGN reached a trading volume of 13357480 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What do top market gurus say about Evogene Ltd [EVGN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EVGN shares is $13.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EVGN stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Evogene Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 08, 2021. While these analysts kept the previous recommendation, Aegis Capital raised their target price to Buy. The new note on the price target was released on July 29, 2021, representing the official price target for Evogene Ltd stock. Previously, the target price had yet another raise to $9, while Cantor Fitzgerald analysts kept a Overweight rating on EVGN stock.
The Average True Range (ATR) for Evogene Ltd is set at 0.30, with the Price to Sales ratio for EVGN stock in the period of the last 12 months amounting to 1.29. The Price to Book ratio for the last quarter was 3.79, with the Price to Cash per share for the same quarter was set at 3.90.
How has EVGN stock performed recently?
Evogene Ltd [EVGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.00. With this latest performance, EVGN shares dropped by -21.38% in over the last four-week period, additionally sinking by -67.68% over the last 6 months – not to mention a drop of -52.41% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVGN stock in for the last two-week period is set at 38.99, with the RSI for the last a single of trading hit 37.92, and the three-weeks RSI is set at 38.61 for Evogene Ltd [EVGN]. The present Moving Average for the last 50 days of trading for this stock 2.82, while it was recorded at 2.39 for the last single week of trading, and 5.92 for the last 200 days.
Evogene Ltd [EVGN]: Deeper insight into the fundamentals
Evogene Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.24 and a Current Ratio set at 4.37.
Insider trade positions for Evogene Ltd [EVGN]
The top three institutional holders of EVGN stocks are: SILVERARC CAPITAL MANAGEMENT, LLC with ownership of 3.08 million shares, which is approximately 6.0837%. MORGAN STANLEY, holding 0.22 million shares of the stock with an approximate value of $$0.14 million in EVGN stocks shares; and MORGAN STANLEY, currently with $$65294.0 in EVGN stock with ownership which is approximately 0.1983%.
